Oncogenic and Stemness Signatures of the High-Risk HCMV Strains in Breast Cancer Progression

被引:17
|
作者
El Baba, Ranim [1 ]
Pasquereau, Sebastien [1 ]
Ahmad, Sandy Haidar [1 ]
Diab-Assaf, Mona [2 ]
Herbein, Georges [1 ,3 ]
机构
[1] Univ Franche Comte, Univ Bourgogne Franche Comte UBFC, Pathogens & Inflammat EPILAB Lab, EA 4266, F-25030 Besancon, France
[2] Lebanese Univ, Mol Canc & Pharmaceut Biol Lab, Beirut 1500, Lebanon
[3] CHU Besancon, Dept Virol, F-25030 Besancon, France
关键词
human cytomegalovirus; CTH cells; PGCCs; HCMV strains; TNBC; paclitaxel; ganciclovir; oncogenesis; CELLS; SARCOMA;
D O I
10.3390/cancers14174271
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Lately, human cytomegalovirus (HCMV) has been progressively implicated in carcinogenesis alongside its oncomodulatory impact. CMV-Transformed Human mammary epithelial cells (CTH) phenotype might be defined by giant cell cycling, whereby the generation of polyploid giant cancer cells (PGCCs) could expedite the acquisition of malignant phenotypes. Herein, the main study objectives were to assess the transformation potential in vitro and evaluate the obtained cellular phenotype, the genetic and molecular features, and the activation of cellular stemness programs of HCMV strains, B544 and B693, which were previously isolated from triple-negative breast cancer (TNBC) biopsies. The strains' sensitivity to paclitaxel and ganciclovir combination therapy was evaluated. A unique molecular landscape was unveiled in the tumor microenvironment of TNBC harboring high-risk HCMV. Overall, the explicit oncogenic and stemness signatures highlight HCMV potential in breast cancer progression thus paving the way for targeted therapies and clinical interventions which prolong the overall survival of breast cancer patients. Background: Human cytomegalovirus (HCMV) oncomodulation, molecular mechanisms, and ability to support polyploid giant cancer cells (PGCCs) generation might underscore its contribution to oncogenesis, especially breast cancers. The heterogeneity of strains can be linked to distinct properties influencing the virus-transforming potential, cancer types induced, and patient's clinical outcomes. Methods: We evaluated the transforming potential in vitro and assessed the acquired cellular phenotype, genetic and molecular features, and stimulation of stemness of HCMV strains, B544 and B693, isolated from EZH2(High)Myc(High) triple-negative breast cancer (TNBC) biopsies. Therapeutic response assessment after paclitaxel (PTX) and ganciclovir (GCV) treatment was conducted in addition to the molecular characterization of the tumor microenvironment (TME). Findings: HCMV-B544 and B693 transformed human mammary epithelial cells (HMECs). We detected multinucleated and lipid droplet-filled PGCCs harboring HCMV. Colony formation was detected and Myc was overexpressed in CMV-Transformed-HMECs (CTH cells). CTH-B544 and B693 stimulated stemness and established an epithelial/mesenchymal hybrid state. HCMV-IE1 was detected in CTH long-term cultures indicating a sustained viral replication. Biopsy B693 unveiled a tumor signature predicting a poor prognosis. CTH-B544 cells were shown to be more sensitive to PTX/GCV therapy. Conclusion: The oncogenic and stemness signatures of HCMV strains accentuate the oncogenic potential of HCMV in breast cancer progression thereby leading the way for targeted therapies and innovative clinical interventions that will improve the overall survival of breast cancer patients.
引用
收藏
页数:18
相关论文
共 50 条
  • [22] Breast Cancer Risk Assessment Models and High-Risk Screening
    Barke, Lora D.
    Freivogel, Mary E.
    RADIOLOGIC CLINICS OF NORTH AMERICA, 2017, 55 (03) : 457 - +
  • [23] High-dose chemotherapy in high-risk breast cancer
    Price, LA
    LANCET, 1998, 352 (9139): : 1551 - 1552
  • [24] High-dose chemotherapy in high-risk breast cancer
    de Boer R.
    Breast Cancer Research, 2 (1)
  • [25] Gene signatures of breast cancer progression and metastasis
    David I Rodenhiser
    Joseph D Andrews
    Theodore A Vandenberg
    Ann F Chambers
    Breast Cancer Research, 13
  • [26] Gene signatures of breast cancer progression and metastasis
    Rodenhiser, David I.
    Andrews, Joseph D.
    Vandenberg, Theodore A.
    Chambers, Ann F.
    BREAST CANCER RESEARCH, 2011, 13 (01)
  • [27] Large-scale tumor-associated collagen signatures identify high-risk breast cancer patients
    Xi, Gangqin
    Guo, Wenhui
    Kang, Deyong
    Ma, Jianli
    Fug, Fangmeng
    Qiu, Lida
    Zheng, Liqin
    He, Jiajia
    Fang, Na
    Chen, Jianhua
    Li, Jingtong
    Zhuo, Shuangmu
    Liao, Xiaoxia
    Tun, Haohua
    Li, Lianhuang
    Zhang, Qingyuan
    Wang, Chuan
    Boppart, Stephen A.
    Chen, Jianxin
    THERANOSTICS, 2021, 11 (07): : 3229 - 3243
  • [28] Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer
    Philipson, Rebecca G.
    Romero, Tahmineh
    Wong, Jessica K.
    Stish, Bradley J.
    Dess, Robert T.
    Spratt, Daniel E.
    Pilar, Avinash
    Reddy, Chandana
    Wedde, Trude B.
    Lilleby, Wolfgang A.
    Fiano, Ryan
    Merrick, Gregory S.
    Stock, Richard G.
    Demanes, D. Jeffrey
    Moran, Brian J.
    Braccioforte, Michelle
    Tran, Phuoc T.
    Martin, Santiago
    Martinez-Monge, Rafael
    Krauss, Daniel J.
    Abu-Isa, Eyad I.
    Valle, Luca
    Chong, Natalie
    Pisansky, Thomas M.
    Choo, C. Richard
    Song, Daniel Y.
    Greco, Stephen
    Deville, Curtiland
    McNutt, Todd
    DeWeese, Theodore L.
    Ross, Ashley E.
    Ciezki, Jay P.
    Tilki, Derya
    Karnes, R. Jeffrey
    Klein, Eric A.
    Tosoian, Jeffrey J.
    Boutros, Paul C.
    Nickols, Nicholas G.
    Bhat, Prashant
    Shabsovich, David
    Juarez, Jesus E.
    Kupelian, Patrick A.
    Rettig, Matthew B.
    Berlin, Alejandro
    Tward, Jonathan D.
    Davis, Brian J.
    Reiter, Robert E.
    Steinberg, Michael L.
    Elashoff, David
    Horwitz, Eric M.
    EUROPEAN UROLOGY, 2021, 80 (02) : 142 - 146
  • [29] Tamoxifen and the prevention of breast cancer in high-risk women
    OBSTETRICS AND GYNECOLOGY, 1999, 94 (04):
  • [30] Epigenetic therapy against high-risk breast cancer
    Lupien, M.
    CANCER RESEARCH, 2021, 81 (04)